Grant Life Sciences Receives Purchase Order from India for Two Million Point-of-Care (POC), 'Rapid' Malaria Tests to Be Delivered by Year-End Monday September 11, 11:53 am ET "This is an important event, because it demonstrates that we are successfully executing our new corporate strategy, part of which is to drive sales through our established marketing channels overseas."
LOS ANGELES--(BUSINESS WIRE)--Sept. 11, 2006--Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences Grant Life Sciences Inc. (OTC BB: GLIF - News) announced today that it has received a purchase order from an arm of the Indian government for two million of its point-of-care (POC), 'rapid' malaria tests, to be delivered by year-end. Grant intends to ship approximately 25 percent of the total order immediately. These malaria tests are part of the 'AccuDx' rapid-test product line to which Grant holds exclusive rights from AccuDx Corp.--a biotechnology company founded by Ravi Pottathil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics. The AccuDx portfolio includes additional rapid tests for HIV-1, HIV-2, for example, and Dengue Fever.
ADVERTISEMENT
"When we acquired exclusive rights to the AccuDx rapid-test portfolio, we said that we expected to generate revenues from these products in specialty diagnostic markets outside of the United States," said Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences. "Certainly, this sizable order from India bears strong testimony to the opportunities ahead of us. Indeed, this order demonstrates that we are making considerable progress toward executing our new corporate strategy: (1) to acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels--as is the case with this significant order from India," said Dr. Lin.
About Grant Life Sciences, Inc.
Grant Life Sciences, a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact: Grant Life Sciences Don Rutherford, 949-521-1232
-------------------------------------------------------------------------------- Source: Grant Life Sciences
Posted by bksundar on :
For the holders of this stock at 0.028 or in that neighbourhood, congrats.
We are rich today !!!
Posted by jos_tul on :
Whats the OS on this one ?
Posted by bksundar on :
126m
Info from my Ameritrade izone account :
Moving Average 50-day 0.02 Moving Average 200-day 0.02 Vol Average 50-day 2,643,600 Vol Average 200-day 3,488,900 52-wk high (1/20/2006) 0.24 52-wk low (11/4/2005) 0.00 Bid 0.04 Ask 0.04 Share Related Items Market Cap 4,427,045 Shares Outstanding 126,487,000 Current P/E Ratio n/a
Posted by bksundar on :
0.041 printed...
Posted by bksundar on :
0.041 * 0.042
Posted by bksundar on :
FIRE ..... 0.0433 * 0.043
Posted by bksundar on :
What a day for me . I think, I will be making above $10,000 today at this rate !!!
Posted by bksundar on :
.046 * 0.0435
Posted by bksundar on :
I hope it reaches 0.08 like in the beginning of the year !!
Then I need not worry about my POS stocks like DDSI, GWGO, GWDB, PMED and ADOT
Posted by IMAKEMONEY on :
nice buck
Posted by bksundar on :
0.048 * 0.047
Row Row Row you boat, Gently down the street, Merrily Merrily Merrily Merrily, Life is but a dream !!
Posted by bksundar on :
I meant 'stream'. What excitement !!!
Posted by bksundar on :
Looks like shake from 0.049 to 0.043 !!!
Posted by bksundar on :
Round Number 2 started....
Posted by bksundar on :
Need to break 0.049...
Posted by stockonyou on :
Looks a perfect time for a profit taking...
Posted by bksundar on :
After so much gain, you bet !!!
Posted by bksundar on :
Back up again... Needs to break 0.049 still
Posted by bksundar on :
So far at 0.0485 . It is almost there. Volume is great too...
Posted by bksundar on :
0.049 reached again... Will it break ??
Posted by bksundar on :
0.054 * 0.053 Wo.. Hoo...
Posted by IMAKEMONEY on :
LOL.Ya baby.
Posted by BooDog on :
wowzer! Had this on my screen list and just got to it LOL should have started with the G's!!
Posted by bksundar on :
I had this on my screen since last week of August and got in at 0.028 . I made some very good money here ....
Posted by BooDog on :
setting for .042 but watching for a lower entry nice move Bksundar. I need to speed up my screening, I've had this on my list since Sat. This is where the fun is...trying to get in on a run on the pull back.
[ September 12, 2006, 09:17: Message edited by: BooDog ]
Posted by bksundar on :
pre-market action is at 0.058 * 0.059 !!!
Posted by BooDog on :
not chasin the truck, learned to shorten my chain a little. LOL tracking the scent though.
Posted by bksundar on :
This would not be a good entry point. Only if you entered already at 0.028 to 0.035. You are better off tracking the scent !!!
Posted by BooDog on :
wow do you see .07? frak! .08 I tottaly am kicking myself!
Posted by bksundar on :
Could reach it, but it is risky to enter at 0.05 levels... In March, it reached 0.08 in one day and went back to the 0.04 levels th enext day.
But who knows. I am not claiming any right to know what happens today. Good luck...
Posted by BooDog on :
quote:Originally posted by bksundar: This would not be a good entry point. Only if you entered already at 0.028 to 0.035. You are better off tracking the scent !!!
Yep I see that, best for .032. I don't mind missing out on this one, just was so close to having it on my radar. 5 months ago I would have been in on the ask. This dog learns new tricks quick. Good Luck BKsundar!
Posted by bksundar on :
But it sure is a good day to take profits...
Posted by bksundar on :
Going crazy now...
Posted by stockonyou on :
congrat to all holders, this was really good.
Posted by bksundar on :
Volume at 6m already !!! I am really rich now...
Posted by bksundar on :
0.06 reached...
Posted by bksundar on :
0.063 now..
Posted by Ace of Spades on :
WoW!!!
Posted by Schwabie on :
Make sure ya'll protect your investment...
Nice volume.
Not chasing.
Posted by BooDog on :
could have gone in for a flip but I agree schwab, safer to wait for the pull back. Pretty darn good contract though. Would have had .054 to .062, not too bad.
Posted by Schwabie on :
b .06 / a .06
Posted by BooDog on :
.058 new base?
Posted by Schwabie on :
quote:Originally posted by BooDog: .058 new base?
NOPE...
Today’s Price Performance as of 10:33am EDT, 9/12/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.055 Last Price 0.0021 +3.96% Today’s Change $0.05 Today’s Open 15,234,058 Above Avg. Today’s Volume
Posted by BooDog on :
nope, was thinking volume and buys would keep it up there. Pulling back pretty good now.
Posted by BooDog on :
pushin er down now eh? bids down to .045 back to the drawing board.... that'll teach me to put off my homework!
Posted by Schwabie on :
YOU GOT IN ? WHAT PRICE ?
DID YOU NOT READ ANYTHING POSTED ?
Posted by BooDog on :
I didn't get in, was thinking of getting in at .054 and would have gotten out at .062. Passed this one up since I missed the first big run. When this settles there should be another PR with how much rev is expected - thinking they will milk it for every penny. may jump in when it gets lower.
Posted by Schwabie on :
IT DOES HAVE POSIBILITIES NO DOUBT.
BUT ALOTTA PROFIT TAKING !
Posted by BooDog on :
quote:Originally posted by Schwabie: YOU GOT IN ? WHAT PRICE ?
DID YOU NOT READ ANYTHING POSTED ?
were you talking to me???? LMAO
Posted by bksundar on :
It went up from 0.028 to max of 0.063. Obviously people are frantically taking profits.
Posted by wadeinni on :
Wow New Out agin!!!!
Press Release Source: Grant Life Sciences Inc.
Grant Life Sciences enters into Memorandum of Understanding (MOU) with Chinese medical device company to manufacture and distribute Grant's point-of-care, rapid diagnostic tests in China and Hong Kong Wednesday September 13, 9:00 am ET "When finalized, this relationship will fit with Grant's new corporate strategy: to (1) acquire products and technologies via in-licensing activities and optimize these products and technologies (2) out-license them for further development and sales and (3) drive sales through our own established marketing channels." -Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences
LOS ANGELES--(BUSINESS WIRE)--Sept. 13, 2006--Grant Life Sciences Inc. (OTC BB: GLIF - News) announced today that it has signed a Memorandum of Understanding (MOU) with GuongDong Kangermei Industry Development Co. Ltd. (GDK) to license the manufacturing and distribution rights of Grant's AccuDx line of rapid, point-of-care (POC) tests in China and Hong Kong. Below is a summary of the key terms of the MOU, which will be used as the basis for a definitive License and Collaboration Agreement between Grant and GDK:
* Grant agrees to license the manufacturing, distribution, and sales rights of certain AccuDx products for the territories of China and Hong Kong to GDK. The AccuDx products include POC tests to detect Hepatitis B and C, HIV 1 and 2, Dengue Fever, and heart attack markers Troponin 1 and Myoglobin. * Grant agrees to use GDK as an OEM (original equipment manufacturer) to produce AccuDx products for the markets outside of China and Hong Kong for an initial period of four years. * All products manufactured by GDK that are to be sold outside of China/Hong Kong shall be handled by Grant. * Grant will own an undisclosed percentage of equity in GDK. * GDK agrees that Grant will have one Director seat. * GDK agrees to pay Grant RMB$1.0 million upfront to facilitate technology transfer.
"When this MOU is finalized, we look forward to a long and mutually beneficial relationship between Grant and GDK," said Huok Xin, CEO of GDK.
"When completed, this relationship with GDK will fit with Grant Life Science's new corporate strategy: to (1) acquire new products and technologies through in-licensing activities and optimize these products and technologies; (2) out-license them for further development and sales; and (3) drive sales through our own established marketing channels," said Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences. "We expect this relationship with GDK will enable Grant to gain access in China to a large consumer market for our technologies and products."
About GDK
GuongDong Kangermei Industry Development Co., Ltd. (GDK) is a medical device company located in GuongDong Province, China, and has established a manufacturing facility and distribution channel in China. GDK is principally involved in the manufacturing of medical instrument sets comprising single-use injection syringes and single-use blood and plasma transfusion sets.
About Grant Life Sciences
Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.
Contact:
Grant Life Sciences Inc. Don Rutherford, 949-521-1232 CFO
Source: Grant Life Sciences Inc.
Posted by Lootcifer on :
Wow can't believe she has huge news like this practically back to back. First Monday now today
Posted by wadeinni on :
Yeah they had the huge purchase order from India in Mondays PR now they're dealing with China and Hong Kong.